RXi plans for $8.7M from private stock sale

By Mass High Tech Staff

Search committee chooses Collins as chancellor of UMass Medical School [August 15, 2008]

Lemelson-MIT Prize winner DeSimone courts Hub RNAi firms [July 3, 2008]

RXi gets $25M max equity deal [February 5, 2009]

Khorova named chief scientific officer at RXi [October 22, 2008]

RXi Pharmaceuticals Corp., a Worcester biopharmaceuticals company focused on RNA interference (RNAi), reports it has entered into a private placement with potential gross proceeds of $8.7 million. The company announced its one million common stock shares available to institutional investors for $8.12 per share.

News of the private placement comes on the heels of RXi’s March welcome to public trading.

RXi Pharmaceuticals (Nasdaq: RXII) plans to use the funds to grow its rxRNA compound line and to apply to general corporate purposes.

Jefferies & Company acted as the lead placement agent, and Natixis Bleichroeder Inc., Broadpoint Securities Group, Inc. and Griffin Securities Inc. acted as co-placement agents.

RXi is a developer of RNAi drugs designed to block genes linked to disease from producing proteins. The company was launched in January 2007 with a scientific advisory board chaired by Craig Mello, winner of a 2006 Nobel prize for his research of RNAi.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.